Public opinions about overdiagnosis:A national community survey by Moynihan, Ray et al.
Bond University
Research Repository
Public opinions about overdiagnosis
Moynihan, Ray; Nickel, Brooke; Hersch, Jolyn; Beller, Elaine; Doust, Jenny; Compton, Shane;
Barratt, Alexandra; Bero, Lisa; McCaffery, Kirsten
Published in:
PLoS One
DOI:
10.1371/journal.pone.0125165
Published: 20/05/2015
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Moynihan, R., Nickel, B., Hersch, J., Beller, E., Doust, J., Compton, S., ... McCaffery, K. (2015). Public opinions
about overdiagnosis: A national community survey. PLoS One, 10(5), [e0125165].
https://doi.org/10.1371/journal.pone.0125165
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 06 Nov 2019
RESEARCH ARTICLE
Public Opinions about Overdiagnosis: A
National Community Survey
Ray Moynihan1*, Brooke Nickel2, Jolyn Hersch2, Elaine Beller1, Jenny Doust1,
Shane Compton3, Alexandra Barratt2, Lisa Bero4, Kirsten McCaffery2
1 Centre for Research in Evidence-Based Practice, Bond University, Robina, Queensland, Australia,
2 School of Public Health, University of Sydney, Sydney, New South Wales, Australia, 3 The Social
Research Centre, Melbourne, Victoria, Australia, 4 Charles Perkins Centre, University of Sydney, Sydney,
New South Wales, Australia
* raymoynihan@bond.edu.au
Abstract
Background
Despite evidence about the "modern epidemic" of overdiagnosis, and expanding disease
definitions that medicalize more people, data are lacking on public views about these is-
sues. Our objective was to measure public perceptions about overdiagnosis and views
about financial ties of panels setting disease definitions.
Methods
We conducted a 15 minute Computer Assisted Telephone Interview with a randomly select-
ed community sample of 500 Australians in January 2014. We iteratively developed and pi-
loted a questionnaire, with a convenience sample (n=20), then with participants recruited by
a research company (n=20). Questions included whether respondents had been informed
about overdiagnosis; opinions on informing people; and views about financial ties among
panels writing disease definitions.
Findings
Our sample was generally representative, but included a higher proportion of females and
seniors, typical of similar surveys. American Association for Public Opinion Research re-
sponse rate was 20% and cooperation rate was 44%. Only 10% (95% CI 8%–13%) of peo-
ple reported ever being told about overdiagnosis by a doctor. 18% (95% CI 11%–28%) of
men who reported having prostate cancer screening, and 10% (95% CI 6%–15%) of
women who reported having mammography said they were told about overdiagnosis. 93%
(95% CI 90%–95%) agreed along with screening benefits, people should be informed about
overdiagnosis. On panels setting disease definitions, 78% (95% CI 74%–82%) felt ties to
pharmaceutical companies inappropriate, and 91% (95% CI 82%–100%) believed panels
should have a minority or no members with ties. Limitations included questionnaire novelty
and complexity.
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Conclusions
A small minority of Australians surveyed, including those reporting being screened for pros-
tate or breast cancer, reported being informed of overdiagnosis; most believed people should
be informed; and a majority felt it inappropriate that doctors with ties to pharmaceutical com-
panies write disease definitions. Results suggest strategies to better inform people about
overdiagnosis, and review disease definition processes, have significant public sympathy.
Introduction
The “modern epidemic” of overdiagnosis is now recognised as an important risk to health [1, 2],
with evidence-based efforts underway to combat it [3]. Overdiagnosis occurs when someone is
diagnosed with a disease that would not have harmed them [2], often as a result of undergoing
screening, and evidence is emerging that many people are overdiagnosed and labelled unneces-
sarily across a range of conditions [4]. An inquiry in the United Kingdom estimated 19% of the
breast cancers detected during mammography screening may be overdiagnosed [5], and the
United States Preventive Services Task Force recently noted there is “convincing evidence that
PSA-based screening leads to substantial overdiagnosis of prostate tumors”, with estimates
ranging from 17% to 50% [6].
There are on-going scientific discussions about the best methods for measuring overdiagno-
sis [7], as well as strong arguments that some degree of overdiagnosis is an inevitable risk of
screening programmes [8], and that attempts to prevent it should not come at the cost of in-
creasing under-diagnosis. Notwithstanding these debates, there is now official recognition of the
need for greater awareness of the problem. As a working group convened under the auspices of
the National Cancer Institute has observed, “Physicians, patients, and the general public must
recognize that overdiagnosis is common and occurs more frequently with cancer screening” [9].
Screening programs are one of many causes of overdiagnosis including technological
changes enabling detection of ever-smaller abnormalities, commercial interests seeking wider
markets, the medicalization of risk and cultural enthusiasm for early detection [2]. Overdiag-
nosis can also be seen as one aspect of much broader processes of biomedicalization [10]. “In
the biomedicalization era” wrote sociologists Clarke and colleagues “what is perhaps most radi-
cal is the biomedicalization of health itself”, an era when “it is no longer necessary to manifest
symptoms to be considered ill or ‘at risk’”[10]. Armstrong has also described the inexorable
rise of “surveillance medicine”, which reconstructs the nature of disease to become “less the ill-
ness per se but rather the semi-pathological pre-illness at-risk state” [11]. More recently, in a
series in The BMJ, researchers are investigating how expanding disease definitions which label
more people with milder symptoms or at lower risks are increasing the potential for overdiag-
nosis, with examples including thyroid cancer [12], gestational diabetes [13], and pulmonary
embolism [14].
A 2013 study of the guideline panels which recently changed definitions of 14 common con-
ditions found a majority widened those definitions—including creating pre-hypertension, ex-
panding the diagnosis of myocardial infarction, and lowering diagnostic thresholds for
Attention Deficit Hyperactivity Disorder [15]. In addition panel publications did not generally
report potential harms of these changes, including risks of overdiagnosis, and among panels
which made disclosures, 75% of members had multiple ties to pharmaceutical companies, in-
cluding those benefiting directly from any increase in populations classified as patients. This
finding of extensive conflicts of interest among medical professionals who define human
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disease is in stark contrast to recommendations from the Institute of Medicine that guideline
panels should wherever possible exclude members with conflicts [16].
While overdiagnosis and expanding disease definitions are recognised as important and re-
lated problems, data on public awareness and views about them are extremely limited. In 2004,
Schwartz and colleagues found widespread enthusiasm for cancer screening, largely unmodi-
fied by awareness of potential harms [17]. More recently Hersch and colleagues published
focus group data on Australian women’s views on overdiagnosis of breast cancer, finding high
enthusiasm for screening and minimal awareness of overdiagnosis, but also a demand for in-
formation about the topic [18]. In 2013 an on-line survey of 317 people invited to cancer
screening found under 10% were informed by their doctor about the risk of overdiagnosis and
overtreatment, and 80% expressed a desire to be informed about these risks [19]. To our
knowledge, no previous survey has asked the general community about perceptions and views
on overdiagnosis. And while there is data on public views about different aspects of industry-
health professional relationships [20, 21], no study has sought community views specifically
about ties of panels which change disease definitions.
We aimed to measure the general community’s awareness and perceptions about overdiag-
nosis and views about financial ties of panels which set disease definitions and diagnostic
thresholds. Notwithstanding important limitations outlined below, we believe our results will
help inform attempts to better communicate about overdiagnosis.
Methods
We conducted a national Computer Assisted Telephone Interview (CATI) survey with 500
members of the Australian community aged 18 years and older, using a randomly selected dual
frame sample—including land-line and mobile phones—during January and February 2014.
The survey questionnaire included items about awareness of overdiagnosis, experience of being
informed about overdiagnosis during screening, enthusiasm for genetic screening—a possible
pathway to overdiagnosis [22]—and attitudes to financial ties of expert panel members who
change disease definitions. It also collected demographic information on age, gender, employ-
ment, education, and cancer history. Questions were iteratively developed jointly by all au-
thors, based on published and unpublished findings including from focus groups on views
about overdiagnosis with 50 women of diverse age and educational background, [18] a qualita-
tive study on patient attitudes [23], and the 2004 survey of attitudes towards screening [17].
Draft items were piloted initially by three authors (RM, BN, JH) with a convenience sample
of 20 adults. Then 20 pilot telephone interviews were conducted by an experienced social re-
search company, the Social Research Centre, which subsequently conducted 500 interviews.
The survey sample size of 500 was chosen as appropriately powered so that the confidence
interval around the proportion responding affirmatively would be approximately 4% either side
of the observed proportion for the expected responses to key questions on awareness of overdi-
agnosis (expected response around 20%), enthusiasm for screening (expected response around
80%), and belief people should be made aware of risks (expected response around 80%).
A dual frame random digit dialling sample design was employed with a 50:50 split between
landline and mobile samples. After calling the randomly selected telephone numbers, inter-
viewers asked to speak with the person in the household aged 18 years or over who had the last
birthday (landlines) or confirmed if the person answering was over 18 years (mobiles). A
slightly modified approach was adopted after approximately 400 interviews, in order to target
more difficult to reach demographic groups, notably males and young adults. Rather than ask-
ing for the person with the last birthday, the modified screening approach requested to speak
with the youngest adult male. Once a potential interview was established, interviewers provided
Public Opinions about Overdiagnosis: A National Community Survey
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information about the research purpose and process, and obtained informed consent. (see Eth-
ics Statement below) Answer options included yes/no answers, and Likert type scales to offer
more options for intensity of response.
The survey took approximately 15 minutes to complete. Key questionnaire questions and
the brief explanation of overdiagnosis offered to participants after the question on unprompted
awareness are listed in Table 1. Other questions are available online (S1 File). An open-ended
item and a separate section on concern and treatment preferences relating to ductal carcinoma
Table 1. Survey Questions.
Survey Question Response Format
On awareness and opinions about overdiagnosis
Have you seen or heard the term ‘over-diagnosis’ before today? Yes
No
Don’t know
A generally accepted view is that over-diagnosis happens when people are
diagnosed with a disease that would never have harmed them. This could be due
to the condition being so slow developing or them displaying only very minor
symptoms. Given this explanation, have you seen or heard the term or concept of
‘over-diagnosis’?
Yes
No
Don’t Know
Has a doctor ever told you that healthy people can be over-diagnosed as a result
of being screened or tested for a disease?
Yes
No
Don’t Know
[For those who reported being screened for prostate or breast cancer]: Were you
told about the risk of over-diagnosis?
Yes
No
Don’t Know
Do you think routine screening tests for healthy people are almost always a good
idea?
Yes
No
Don’t Know
When healthy people are considering having a screening test—along with being
told about the potential beneﬁts of the screening test—do you agree or disagree
that they should be informed about the potential risk of over-diagnosis?
7 point Likert scale:
Completely Agree
to
Completely Disagree
On enthusiasm for genetic screening
Imagine that there was a genetic screening test which could analyse your genes
and identify all the diseases you may ever get, for which some had effective
treatments and some did not. Would you be likely or unlikely to have that
screening test?
7 point Likert scale:
Completely Likely
To
Completely Unlikely
Imagine now that the results of the genetic screening test were often uncertain,
and the predictions could be wrong. Would you be likely or unlikely then to have
that screening test?
7 point Likert scale:
Completely Likely
To
Completely Unlikely
On expert disease panel ties to pharmaceutical companies
From time to time, doctors who specialise in a particular disease will come
together to discuss the characteristics of that disease, to decide who should be
diagnosed with it and who requires treatment for it. These are called panels and
currently some doctors on these panels have ﬁnancial ties with pharmaceutical
companies who market drugs for that disease and some do not. Is it appropriate or
inappropriate for doctors who have ﬁnancial ties with pharmaceutical companies to
be members of these panels?
7 point Likert scale:
Completely
Appropriate
to
Completely
Inappropriate
Ideally, what proportion of the panel should be made up of doctors with ﬁnancial
ties to pharmaceutical companies who market drugs for that disease?
None
A minority
A majority
doi:10.1371/journal.pone.0125165.t001
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in situ terminology are being separately analysed and reported elsewhere. At the questionnaire
conclusion, participants were asked if they would like to participate in a follow-up qualitative
interview about similar topics, and if so, provide name and contact details.
There is debate in the survey literature about different ways to calculate outcome rates, with
a key question being to what extent households that could not be contacted or screened are in-
cluded in the denominator. To assess our sampling strategy we calculated the response rate
and cooperation rate as per recommendations and formulae from the American Association
for Public Opinion Research [24]. The AAPOR response rate includes in its denominator esti-
mations of the proportion of cases of unknown eligibility which is actually eligible, and calcula-
tions involve all households including those where no contact at all was made. The AAPOR
cooperation rate excludes un-contacted households, and calculates the proportion of those
contacted who cooperated.
No weighting was applied to primary results. For adjusted results, a two-stage weighting
process was used where-by a pre-weight to adjust for the overlapping sample was calculated for
people with and without a mobile phone. People have varying chances of selection in a dual-
frame sample and those with a landline and mobile phone have multiple chances of selection.
After these pre-weights were calculated, post-stratification weights were created using rim
weighting to adjust weighted proportions to comply with population proportions from four
benchmarks obtained from the Australian Bureau of Statistics for gender, age, location and ed-
ucation [25,26]. All results were analyzed descriptively using IBM SPSS Statistics 22, using pro-
portions and confidence intervals. Chi-square tests of association were used to determine the
strength of association between demographic variables and four key questions. Variables sig-
nificant at the 5% level in chi-square analyses were fitted in multivariable models.
Ethics Statement
Ethics approval was granted by the Bond University Human Research Ethics Committee,
BUHREC, whose comments helped refine questionnaire text. (Approval #RO1765) Partici-
pants were assured responses would be anonymous and not recorded, and in order to maxi-
mise informed consent, a Participant Information Sheet was developed and made available to
be read on request, and posted on accessible websites. The information sheet and the process
for seeking informed consent were explicitly approved by BUHREC. Interviewers underwent a
tailored training session in preparation for the survey, covering topics including sensitive sub-
ject matter training and strategies for handling distressed respondents.
Results
The random sample selection process commenced with 4,268 numbers available, from which
4,156 landline and mobile calls were initiated, and 3,307 eligible numbers identified. Contact
was made with 1,282 numbers from which 500 completed interviews were achieved, 251 from
the landline sample and 249 from the mobile phone sample, in addition to the 20 pilot inter-
views, and 8 mid-survey terminated interviews (Fig 1). The response rate was 20.4% (AAPOR,
RR3) and the cooperation rate 43.8% (AAPOR, COOP3).
The sample was generally representative, but included a higher proportion of women and
older adults than the general Australian community, as is typical with telephone based health
surveys, and slightly higher levels of education. (Table 2) All proportions reported here are un-
adjusted, and both adjusted and unadjusted results are available in Table 3, demonstrating gen-
erally minimal impact of adjustment.
Of all participants, 63% (95% CI 58%-67%) said they had heard or seen the word overdiag-
nosis before, although following a brief explanation of the term to all participants (Table 1) the
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number fell to 50% (95% CI: 45%-54%). Only 10% of people said they had ever been told by a
doctor that overdiagnosis was a risk of being screened or tested, (95% CI 8%-13%). Only 18%
of men who reported having had prostate cancer screening (95% CI 11%-28%) and 10% of
women who reported having had a mammogram (95% CI 6%-15%) said they were told about
the risk of overdiagnosis. 76% of participants (95% CI 72%-80%) agreed screening tests were
almost always a good idea and 93% (95% CI 90%-95%) agreed (88% completely or mostly
agreed) that along with the benefits of screening, people should be informed about the risk of
overdiagnosis. (Fig 2).
Asked about enthusiasm for a genetic screening test, the community was split almost equal-
ly, with 49% likely to have a screening test, (95% CI 44%-53%) and 45% unlikely,(95% CI 41%-
50%). When asked to imagine the results of genetic screening tests were often uncertain and
predictions potentially wrong, enthusiasm waned dramatically, with 28% likely, (95% CI 25%-
33%) and 67% unlikely, (95% CI 63%-71%) to undergo tests.
Fig 1. Participant recruitment for Computer Assisted Telephone Interview survey of 500 Australians. *Ineligible participants included: persons under
age 18 years; those with a medical condition rendering them physically unable to complete the interview; people with language difficulties; respondent away
for duration of fieldwork; people claiming to have done survey or named person not known.
doi:10.1371/journal.pone.0125165.g001
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In response to questions about panels which set disease definitions, 78% (95% CI 74%-82%)
felt it inappropriate (72% completely or mostly inappropriate) for members to have financial
ties to pharmaceutical companies. (Fig 3) Asked what proportion of panel members would ide-
ally have financial ties to pharmaceutical companies, 55% (95% CI 50%-59%) said there should
be no panel members with ties, 36% (95% CI 32%-40%) said a minority—less than 50%, and
5% (95% CI 3%-7%) said a majority—50% or more. At the conclusion of the survey, 81% of all
participants volunteered to take part in a qualitative follow-up study. The number of refusals to
answer questions was negligible.
For four key questions—unprompted awareness of overdiagnosis, whether participants had
been informed about overdiagnosis, merits of routine information about overdiagnosis, and
appropriateness of financial ties for disease panels—we looked for associations with 5 key de-
mographics: age, gender, employment, education and cancer history. For gender and employ-
ment, we found no significant associations. Responses to unprompted awareness of the term
overdiagnosis had significant associations with age, education status and cancer history. After
re-coding multiple categories for age into two categories above and below the median age, and
removing “don’t knows” and refusals, among those aged 53 and younger, 57% said yes they
had heard or seen the term, while for those older than 53 years, 71% said yes, (chi-square 9.7,
p = 0.002). For those with a history of cancer, 76% said yes they had heard or seen the term,
and for those without 61% said yes (chi-square 5.5, p = 0.019). After re-coding the highest level
of education into two categories, among those with education up to and including year 12(~age
17), 51% said they were aware of the term, while for those with a post-year 12 education the
Table 2. Characteristics of survey respondents.
Characteristic No. of Survey Respondents n = 500 (%)
Age, y
18–29 76 (15.2) *(21.4)
30–49 139 (27.8) * (36.5)
50–69 209 (41.8) * (29.5)
70 76 (15.2) * (12.7)
Sex
Men 218 (43.6) * (49.4)
Women 282 (56.4) * (50.6)
Education **
<High school 74 (14.8) * (26.9)
High school graduate 169 (33.8) * (38.7)
Bachelor degree/advanced diploma 168 (33.6) * (26.5)
>Bachelor degree 89 (17.8) * (7.7)
Employment
Employed 298 (59.6)
Unemployed 20 (4)
Not working*** 182 (36.4)
Cancer diagnosis
Yes 70 (14.0)
No 430 (86.0)
*Australian population data from the Australian Bureau of Statistics 2011 Census;
** High school normally completed at age 17;
*** Not in labour force (e.g. student, retired)
doi:10.1371/journal.pone.0125165.t002
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figure was 68%, (chi-square 12, p = 0.001). The only other significant association also involved
education levels: those with higher levels were slightly more likely to report a doctor had in-
formed them about overdiagnosis (13% vs 6%; chi square 5.0, p = 0.025).
The only key outcome that had more than one significant association with a demographic
variable was the question about having heard of the term ‘overdiagnosis’. Therefore, age (above
and below the median age), educational level (above and equal to or below year 12 attainment)
and history of cancer diagnosis were used as predictors in multivariable logistic regression. All
were significant. The adjusted odds ratio for reporting having heard of overdiagnosis was 1.8
for the older age group (p = 0.003, 95% CI 1.2 to 2.7), 2.2 for educational level above year 12
(p = 0.001, 95% CI 1.5 to 3.4) and 1.9 for those with a history of cancer diagnosis (p = 0.048,
95% CI 1.0 to 3.4).
Discussion
Our community survey found a large majority of adults reporting they had not been informed
about the risk of overdiagnosis attached to screening tests, and a large majority expressing the
view that along with screening benefits, people should be informed of the risk of overdiagnosis.
Despite strong evidence overdiagnosis is a significant risk of prostate cancer screening [6], 81%
of men who reported being screened said they had not been told; among women who reported
Table 3. Main results of national community survey on overdiagnosis.
On overdiagnosis Unadjusted Adjusted*
Yes/Agree No/Disagree Don’t know/
neither/refused
Yes/Agree No/Disagree Don’t know/
neither/refused
n(%)(95%CI) n(%)(95%CI) n(%)(95%CI) %(95%CI) %(95%CI) %(95% CI)
Seen or heard term ‘overdiagnosis’ before? 313(62.6)
(58.2–66.8)
181(36.2)
(32.0–40.6)
6(1.2)(0.5–2.7) 57.4
(52.9–61.8)
41.1
(36.7–45.4)
1.5(0.8–3.3)
Doctor ever told you about overdiagnosis? 52(10.4)
(7.9–13.5)
443(88.6)
(85.4–91.2)
5(1.0)(0.4–2.5) 9.7(7.2–12.6) 89.5
(86.3–91.9)
0.8(0.3–2.2)
If screened for prostate cancer, told of
overdiagnosis?
16(18.2)
(11.1–28.1)
71(80.7)
(70.6–88.0)
1(1.1)(0.1–7.1) 15.8
(9.2–26.3)
83.1
(72.4–89.9)
1.1(0.1–7.6)
If screened for breast cancer, told of
overdiagnosis?
18(9.7)
(6.0–15.1)
162(87.1)
(81.2–91.4)
6(3.2)(1.3–7.2) 10.8
(6.5–17.3)
86.4
(79.5–91.3)
2.9(0.9–7.3)
Think routine screening almost always good
idea?
382(76.4)
(72.4–80.0)
85(17.0)
(13.9–20.7)
33(6.6)(4.7–9.2) 79.0
(75.1–82.4)
15.1
(12.1–18.5)
6.0(4–8.3)
Should people be informed about risk of
overdiagnosis?
465(93.0)
(90.3–95)
18(3.6)(2.2–5.7) 17(3.4)(2.1–5.5) 93.4
(90.8–95.4)
3.5(2.4–6) 3.0(1.9–5.3)
On genetic screening Likely Unlikely Don’t know/
neither
Likely Unlikely Don’t know/
neither
Likely or unlikely to have genetic screening
test?
243(48.6)
(44.2–53.1)
226(45.2)
(40.8–49.7)
31(6.2)(4.3–8.8) 51.0
(46.5–55.5)
42.5
(38.2–47.1)
6.5(4.7–9.2)
If results uncertain, likely or unlikely to have
test?
142(28.4)
(24.5–32.6)
335(67.0)
(62.7–71.1)
23(4.6)(3–6.9) 31.0
(27.2–35.5)
64.0
(59.6–68.2)
4.8(3.2–7.2)
On ﬁnancial ties of disease-deﬁning
panels
Appropriate Inappropriate Don’t know/
neither/refused
Appropriate Inappropriate Don’t know/
neither/refused
Appropriate or inappropriate for doctors with
ties to pharmaceutical companies to be
panel members?
71(14.2)
(11.3–17.6)
391(78.2)
(74.3–81.7)
38(7.6)
(5.5–10.4)
16.2
(13–19.6)
75.6
(71.6–79.3)
8.1(5.8–10.8)
*Adjustment involved two-step, rim weighting as described in Methods; due to rounding some rows do not add to 100%; calculation of Conﬁdence
Intervals includes continuity correction
doi:10.1371/journal.pone.0125165.t003
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Fig 2. Community views about availability of information on overdiagnosis.
doi:10.1371/journal.pone.0125165.g002
Fig 3. Community views about financial ties of panel members who set disease definitions.
doi:10.1371/journal.pone.0125165.g003
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having breast cancer screening, where overdiagnosis is also now an established risk [5], 87%
said they hadn’t been informed.
Over two-thirds of Australians surveyed felt it was completely or mostly inappropriate for
doctors with financial ties to pharmaceutical companies to serve on panels which set disease
definitions. Moreover, when asked how these panels should ideally be constituted, just over
half of all participants said they should have no doctors with financial ties.
Against a background of concern that widespread promotion of genetic screening could
produce new vectors for overdiagnosis [22], we found public enthusiasm might be modified if
people were informed the results of screening tests could be uncertain or potentially wrong.
Given the propensity of media coverage to over-promote benefits and minimise harms [27],
our findings suggest routine provision of information about the limitations and potential
harms of screening tests may be desirable.
Our study has several important limitations. As part of the survey methodology we axiomat-
ically relied solely on unverified self-reports. While previous data suggests telephone survey
self-reports of screening are reliable indicators of actual behaviour [28], some of the large ma-
jority who reported not being informed about overdiagnosis may in fact have been informed.
Secondly, because this is a new area of inquiry, our questionnaire has not been used before,
apart from the question on enthusiasm for screening taken with minor modification from a
previously published national survey [17]. While new items were rigorously piloted by the re-
search team and social research company using a multi-stage pilot process with 40 adults, and
explicit efforts were made to ensure questions were not leading, we cannot exclude the possibil-
ity some responses may be influenced by the questions. A third limitation arises from the com-
plexity of the material, though there was a strong focus on comprehensibility and clarity in
questionnaire development and interviewer training.
A final limitation arises from the AAPOR response rate of 20.4% and cooperation rate of
43.8%. While modest, these rates are common and considered satisfactory for community sur-
veys of this type. In 2012 the highly regarded Pew Research Centre stated its standard tele-
phone surveys were achieving an AAPOR response rate of 9%, and cooperation rate of 14%,
and that the 9% response rate was similar to that achieved by other major survey organisations
[29]. With the outcome rates achieved there is a possibility of systematically different responses
between respondents and non-respondents, though this possibility is lessened by the general
representativeness of sample respondents.
Alongside limitations, the study has important strengths. In the context of growing evidence
about overdiagnosis this is to our knowledge the first national telephone survey to assess how
the general community reports being informed about overdiagnosis, finding both a deficit of
information and a desire for it. Secondly, we gathered rare and novel data on community atti-
tudes about the timely question of who should most appropriately be setting diagnostic criteria
which determine the nature and extent of human pathology. And finally, our random sample
was generally representative of the Australian community, achieved in part as a result of our
dual frame method, reaching both landline-users and the fast growing demographic of mobile-
only users, now estimated to be more than 20% of phone users in Australia [30], and 38% in
the United States [31]. Moreover, generally negligible differences between adjusted and unad-
justed results strengthen representativeness and generalizability, and potential applicability to
other nations with similar demographics.
There is extremely limited data on public awareness about overdiagnosis. A small on-line
survey limited to individuals who had been invited to undergo cancer screening—reported
briefly as a research letter in 2013—found only 9.5% reported they’d been informed by a physi-
cian about the risk of overdiagnosis and overtreatment, and 80% felt people should be routinely
informed of such screening harms [19]. Similarly our survey found only a small proportion
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reported being told of these harms, and 88% completely or mostly agreed people should be in-
formed about the risk of overdiagnosis, echoing findings from a 2002 survey of around 650
Australian women, which found over 90% wanted to receive information about false results or
mammogram side effects [32]. This strong community desire for information about harms is
set against a backdrop of widespread enthusiasm for screening. In 2004 Schwartz and col-
leagues found 87% agreed routine cancer screening was almost always a good idea [17], while
76% agreed with a similar proposition in our survey a decade later.
There are mixed findings on public attitudes to financial ties between health professionals
and industry. Some studies suggest trial participants want information about investigator fi-
nancial ties, but are not deterred by them [20], while other studies find concern strongest
where the tie brings direct benefits, such as the professional being paid research recruitment
fees [21]. To our knowledge, no previous study has investigated public opinions about the
pharmaceutical company ties of panels which set disease definitions. Our finding of strong
public antipathy to these ties is significant and timely: in tune with Institute of Medicine rec-
ommendations to minimise and eliminate them [16] but in contrast to current reality, where
many panel members have such ties [15].
In light of the limitations of this telephone survey, and the complexity of the material cov-
ered, caution in interpretation is appropriate. In 2014 researchers in the United Kingdom re-
ported that even written information about overdiagnosis and mammography was not well
understood [33]. However, despite that complexity, at the completion of our survey, around
400 of the 500 participants, ultimately shared personal details and agreed to take part in a fol-
low-up qualitative research project, underscoring not only a positive survey experience, but
suggesting a public hunger to learn more about overdiagnosis and related issues.
Responding to overdiagnosis also poses complex challenges. Some degree of overdiagnosis
is inevitable whenever healthy individuals are screened [8], on-going monitoring of screening
programmes may reveal new technologies that can reduce that risk [7], and early detection can
offer genuine opportunities for lifestyle changes or other preventive strategies. While increas-
ing numbers of research projects are underway worldwide investigating the nature and extent
of overdiagnosis, these survey findings, notwithstanding limitations and complexities, point to
the need to find ways to better communicate with the community about the problem. Not least
to facilitate more informed decision making, but more broadly, as Clarke suggests [10], to en-
able “greater democratic participation” in shaping the future of relationships between people
and their health care.
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